Stem Cell News: Breaking Stem Cell News, Comments and Articles. - Page: 3

During CA Pertussis Outbreak, Whole-Cell Vaccine More Effective Than Acellular Vaccine

Whole-cell pertussis vaccines were more effective at protecting against pertussis than acellular pertussis vaccines during a large recent outbreak, according to a new Kaiser Permanente study published in Pediatrics. Whole-cell pertussis vaccines, als...

Outcome In Head And Neck Cancer Predicted By Genetic Diversity Within Tumors

A new measure of the heterogeneity - the variety of genetic mutations - of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer. In the May 20 issue of the journal Cancer, investigat...

EMD Millipore, PharmaCell In Cell Development Pact

Will use bioreactor technology for large-scale production

Jennerex Announces Completion of Enrollment in Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer

SAN FRANCISCO, CA -- (Marketwired) -- 05/21/13 -- Jennerex Biotherapeutics, Inc., a private, clinical-stage biotechnology company focused on the development and commercialization of best-in-class targeted oncolytic immunotherapies for solid tumors, today announced that it completed enrollment of 120 patients in the TRAVERSE study, a global randomized Phase 2b clinical trial evaluating the efficac...

Genetic diversity predicts outcomes in head and neck cancer

A new measure of the heterogeneity – the variety of genetic mutations – of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer. In the May 20 issue of the journal Cancer, inves...

BrainStorm Provides Update on Clinical Trial and Scientific Conference Activities

NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwired) -- 05/21/13 -- BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today provided an update on the company's current and upcoming clinical trial and scientific conference activities. Clinical Trial Activities Brainstorm recently performed the 5th transplantation in...

Medistem, Inc. Appoints Herm Rosenman to Board of Directors

SAN DIEGO, CA -- (Marketwired) -- 05/21/13 -- Medistem, Inc. (PINKSHEETS: MEDS), today announced that it has appointed Herm Rosenman to its Board of Directors and Chairman of the Audit Committee. Mr. Rosenman was Senior Vice President and Chief Financial Officer of Gen-Probe, Inc., from 2001, through its IPO in 2002, until its acquisition by Hologic, Inc., in August 2012 for $3.7 billion. "We we...

X-Ray Diffraction Shows How Frog Embryos Could Help Thwart Disease

An international team of scientists using a new X-ray method recorded the internal structure and cell movement inside a living frog embryo in greater detail than ever before. This result showcases a new method to advance biological research and the s...

Keeping stem cells strong

(California Institute of Technology) A team of researchers led by biologists at the California Institute of Technology has found that, in mouse models, the molecule microRNA-146a acts as a critical regulator and protector of blood-forming stem cells...

Single-cell transfection tool enables added control for biological studies

(Northwestern University) Northwestern researchers have developed a novel tool for single-cell transfection, in which they deliver molecules into targeted cells through temporary nanopores in the cell membrane created by a localized electric field.

Insight into the dazzling impact of insulin in cells

(Garvan Institute of Medical Research) Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes. The breakthrough...

Racial disparities in the surgical management of non-small cell lung cancer

(American Thoracic Society) The surgical management of non-small cell lung cancer in US hospitals varies widely depending on the race of the patient, according to a new study.

Multiple Target ALS Drug Ready for Genervon's Phase 2 Trial

Multiple targets, highly effective, breakthrough therapy for ALS sufferers may now be within reach. Winston Ko, the CEO of Genervon Biopharmaceuticals, will be presenting on Friday at the Neurotech Conference in San Francisco that its endogenous regulatory drug GM604 modulates over 80 ALS related gene targets interactively and dynamically through 12 pathwa...

Understanding and targeting cancer stem cells: therapeutic implications and challenges

Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells

T-bet in the spot light: roles in distinct T-cell fate determination

A bystander cell-based GM-CSF secreting vaccine synergizes with a low dose of cyclophosphamide and induces therapeutic immune responses against murine hepatocellular carcinoma

Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR

Role of LM23 in cell proliferation and apoptosis and its expression during the testis development

Clinical outcomes in patients with stage I non-seminomatous germ cell cancer

T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10

CD52 is an important target for depleting antibodies; however, its physiological ligand and function have been unclear. Harrison and colleagues show that soluble CD52 is used by certain CD4+ cells to suppress target cells via the inhibitory receptor...

Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility

Pfizer to Continue Evaluation of Inotuzumab Ozogamicin in Other Hematologic Malignancies Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgk...

AmeriCares Disaster Response Team Headed to Oklahoma

STAMFORD, Conn., May 20, 2013 /PRNewswire-USNewswire/ -- AmeriCares is deploying an emergency response team to Oklahoma City to coordinate deliveries of relief supplies and medical aid for tornado survivors. The aid organization has reached out to health clinics, food banks and nonprofit organizations in the region with offers of assistance. "We expect to have a team on the ground in Ok...

Factors influencing the efficiency of generating genetically engineered pigs by nuclear transfer: multi-factorial analysis of a large data set

Background: Somatic cell nuclear transfer (SCNT) using genetically engineered donor cells is currently the most widely used strategy to generate tailored pig models for biomedical research. Although this approach facilitates a similar spectrum of gen...

[Stemline Therapeutics] nets $56.4mm through public sale of shares

[Stemline Therapeutics Inc.] (developing treatments that target cancer stem cells and tumor bulk) netted $56.4mm through the public sale of 4mm shares at $14.50. Proceeds will go towards Phase II trials of glioma candidate SL701 and SL401 for orphan...